Rashleigh S P, Kusher D I, Endicott J N, Rossi A R, Djeu J Y
Division of Otolaryngology-Head and Neck Surgery, University of South Florida, School of Medicine, Tampa, USA.
Arch Otolaryngol Head Neck Surg. 1996 May;122(5):541-7. doi: 10.1001/archotol.1996.01890170073014.
To examine the capacity of interleukin-2 (IL-2) and interleukin-12 (IL-12) to modulate the cytolytic activity of peripheral blood mononuclear cells against squamous cell carcinoma, and to determine whether peripheral blood mononuclear cells from healthy donors respond differently to IL-12 than do peripheral blood mononuclear cells from patients with head and neck squamous cell carcinoma.
Case-comparison study of a consecutive sample of patients with head and neck squamous cell carcinoma who were scheduled to undergo surgical excision.
The study included 10 patients with stage III or IV carcinoma matched with 10 volunteer blood donors.
Isolated peripheral blood mononuclear cells from patients and volunteers were treated with IL-2, 10 U/mL and 100 U/mL; IL-12, 1 U/mL or 10 U/mL; or a combination of IL-2 and IL-12.
The combination of IL-2 and IL-12 consistently produced the greatest activation cytolysis than either cytokine alone at all concentrations tested. This increased activity against a squamous cell carcinoma cell line was seen in lymphocytes from volunteers and patients.
Our findings suggest a new treatment regimen for the patient with head and neck cancer that uses immunomodulation with a combination of cytokines.
研究白细胞介素-2（IL-2）和白细胞介素-12（IL-12）调节外周血单个核细胞对鳞状细胞癌的细胞溶解活性的能力，并确定健康供体的外周血单个核细胞对IL-12的反应是否与头颈部鳞状细胞癌患者的外周血单个核细胞不同。
对计划接受手术切除的头颈部鳞状细胞癌患者的连续样本进行病例对照研究。
该研究纳入了10例III期或IV期癌症患者，并与10名志愿献血者进行匹配。
从患者和志愿者中分离出的外周血单个核细胞分别用10 U/mL和100 U/mL的IL-2、1 U/mL或10 U/mL的IL-12，或IL-2与IL-12的组合进行处理。
在所有测试浓度下，IL-2和IL-12的组合始终比单独使用任何一种细胞因子产生更大的激活细胞溶解作用。在志愿者和患者的淋巴细胞中均观察到对鳞状细胞癌细胞系的活性增加。
我们的研究结果表明，对于头颈部癌症患者，一种使用细胞因子组合进行免疫调节的新治疗方案。
